Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
QualFatigue study: which factors influence the use of specific interventions for breast cancer survivors with fatigue? A cross-sectional exploratory study.
Charles C, Di Meglio A, Arnedos M, Arvis J, Baciarello G, Blanchard P, Djehal N, Dumas A, Hollbecque A, Martin E, Matias M, Menvielle G, Zingarello A, Dauchy S, Vaz-Luis I. Charles C, et al. Among authors: baciarello g. Support Care Cancer. 2021 Aug;29(8):4827-4834. doi: 10.1007/s00520-021-06040-z. Epub 2021 Feb 5. Support Care Cancer. 2021. PMID: 33547524
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
Flippot R, Patrikidou A, Aldea M, Colomba E, Lavaud P, Albigès L, Naoun N, Blanchard P, Terlizzi M, Garcia C, Bernard-Tessier A, Fuerea A, Di Palma M, Escudier B, Loriot Y, Baciarello G, Fizazi K. Flippot R, et al. Among authors: baciarello g. Drugs. 2022 May;82(7):719-733. doi: 10.1007/s40265-022-01703-5. Epub 2022 May 5. Drugs. 2022. PMID: 35511402 Review.
Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].
Gizzi M, Oberic L, Massard C, Poterie A, Le Teuff G, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K. Gizzi M, et al. Among authors: baciarello g. Eur J Cancer. 2017 Apr;75:333. doi: 10.1016/j.ejca.2017.02.014. Epub 2017 Mar 7. Eur J Cancer. 2017. PMID: 28283351 No abstract available.
Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.
Dumont C, Baciarello G, Bosset PO, Lavaud P, Colomba E, Massard C, Loriot Y, Albiges L, Blanchard P, Bossi A, Nenan S, Fizazi K. Dumont C, et al. Among authors: baciarello g. Clin Genitourin Cancer. 2020 Dec;18(6):444-451. doi: 10.1016/j.clgc.2020.03.017. Epub 2020 Apr 7. Clin Genitourin Cancer. 2020. PMID: 32349927 Clinical Trial.
Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.
Fuerea A, Baciarello G, Patrikidou A, Albigès L, Massard C, Di Palma M, Escudier B, Fizazi K, Loriot Y. Fuerea A, et al. Among authors: baciarello g. Eur J Cancer. 2016 Jul;61:44-51. doi: 10.1016/j.ejca.2016.03.070. Epub 2016 May 3. Eur J Cancer. 2016. PMID: 27151554 Clinical Trial.
[Management of metastatic testicular germ cell tumors].
Lavaud P, Baciarello G, Fizazi K. Lavaud P, et al. Among authors: baciarello g. Bull Cancer. 2019 Oct;106(10):896-902. doi: 10.1016/j.bulcan.2019.05.004. Epub 2019 Aug 26. Bull Cancer. 2019. PMID: 31466695 Review. French.
66 results